Tempest Therapeutics Inc (US: TPST) — Healthcare · Share Price, Chart & Market Data
About: Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.79 (-0.56%)
TPSTTempest Therapeutics Inc
Loading watchlist status…
Trade TPST now
Tempest Therapeutics Inc share price
TPST price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 12:16 pm GMT+0
TPST price performance
1.13%
5D
3.468%
1M
-39.322%
YTD
-77.139%
1Y
TPST price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 12:16 pm GMT+0
TPST details
TPST Market Signals